STOCK TITAN

Inhibrx Biosciences combo posts 62.7% response rate

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Inhibrx Biosciences, Inc. reported updated Phase 1/2 results for ozekibart plus irinotecan and temozolomide in relapsed or refractory Ewing sarcoma: among 51 response-evaluable patients, the overall response rate was 62.7% and the disease control rate was 86.3%. The study enrolled and treated 60 patients, including 9 adolescents; the results included 2 complete responses, 30 partial responses and 12 cases of stable disease.

As of September 18, 2026, median progression-free survival was 6.0 months (95% CI: 4.6–7.4). Eighteen patients had clinical benefit lasting more than 6 months, including one ongoing partial response lasting more than 2 years. The company described the safety profile as acceptable and manageable, with no evidence of unexpected cumulative hepatotoxicity. The FDA accepted Inhibrx’s biologics license application for potential ozekibart approval in conventional chondrosarcoma.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointPhase 1/2 combination reported a 62.7% overall response rate and 86.3% disease control rate.
  • Moderate pointFDA accepted the BLA for potential ozekibart approval in conventional chondrosarcoma.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Patients treated 60 patients Phase 1/2 study; included 9 adolescent patients
Response-evaluable patients 51 patients Ewing sarcoma study
Overall response rate 62.7% Among 51 response-evaluable patients
Disease control rate 86.3% Among 51 response-evaluable patients
Median progression-free survival 6.0 months As of the September 18, 2026 data cutoff; 95% CI: 4.6–7.4 months
Patients with clinical benefit exceeding 6 months 18 patients Included 1 complete response, 1 stable disease and 16 partial responses
Patients remaining progression-free 14 patients Response-evaluable patients at the September 18, 2026 data cutoff
overall response rate (ORR) medical
"an overall response rate (ORR) of 62.7%"
Overall response rate (ORR) is the percentage of trial participants whose disease measurably improves—typically tumor shrinkage or disappearance—according to predefined medical criteria. Investors watch ORR because it provides an early, concrete signal of a therapy’s effectiveness and commercial potential, similar to seeing what share of products in a test batch actually work before deciding to back wider production.
Disease Control Rate (DCR) medical
"resulting in a Disease Control Rate (DCR) of 86.3%"
The disease control rate (DCR) is the share of patients in a clinical trial whose cancer either shrinks, disappears, or does not get worse for a predefined period after treatment. For investors, DCR is a practical measure of a drug’s ability to halt disease progression — akin to counting how many cars in a fleet are kept running or fixed after a repair — and can influence a therapy’s regulatory prospects, market potential, and perceived risk.
median progression free survival (mPFS) medical
"The median progression free survival (mPFS) was 6.0 months"
Median progression-free survival (mPFS) is the amount of time from the start of a treatment until half the patients in a study have either had their disease get worse or have died; think of it as the middle point in a group’s ‘time until worsening’ clock. Investors watch mPFS because it measures a drug’s ability to delay disease progression, which often influences regulatory approval chances, market demand, pricing power and revenue projections.
stable disease (SD) medical
"12 patients achieved stable disease (SD)"
Stable disease (SD) describes a situation in cancer care and clinical trials where a tumor neither meaningfully shrinks nor grows after treatment — it stays roughly the same size. For investors, SD is a key clinical outcome because it can signal a drug is controlling disease progression, potentially extending patient life or delaying costly interventions, which influences regulatory decisions, market potential and the perceived value of a therapy.
complete responses (CRs) medical
"comprising 2 complete responses (CRs)"
partial responses (PRs) medical
"and 30 partial responses (PRs)"
Partial responses (PRs) are clinical trial results showing that a therapy has meaningfully reduced disease burden in some patients without eliminating it entirely. For investors, PRs signal that a treatment is having a real effect — like a visible shrinkage in a tumor — which can de-risk a program, support future trials or approvals, and influence a company's valuation even though the outcome falls short of a complete cure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What response rates did INBX report for ozekibart in Ewing sarcoma?

Among 51 response-evaluable patients, the combination had a 62.7% overall response rate and an 86.3% disease control rate.

How many INBX study patients remained progression-free?

At the September 18, 2026 data cutoff, 14 response-evaluable patients remained progression-free, including 2 with a progression-free survival duration exceeding 12 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FALSE000200791900020079192026-11-172026-11-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2026
INHIBRX BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)  
Delaware001-4203199-0613523
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
11025 N. Torrey Pines Road, Suite 140
La Jolla, CA 92037
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (858) 795-4220
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareINBXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 8.01. Other Events.
On November 17, 2026, Inhibrx Biosciences, Inc. (“Inhibrx” or the “Company”) issued a press release announcing updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 agonist, in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society 2026 Annual Meeting.
The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1
Press Release issued by Inhibrx Biosciences, Inc. on November 17, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 17, 2026
INHIBRX BIOSCIENCES, INC.
By:/s/ Kelly Deck
Name:Kelly Deck
Title:Chief Financial Officer

Exhibit 99.1
inhibrxlogo-large.jpg

Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;
- 86.3% DCR, with durable responses observed in heavily pretreated patients
SAN DIEGO, CA - November 17, 2026/PRNewswire — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.
“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas,” said Mark Lappe, Chief Executive Officer of Inhibrx. “In relapsed or refractory Ewing sarcoma, achieving a 62.7% overall response rate, an 86.3% disease control rate, and clinically meaningful durability is particularly compelling in a population that has exhausted effective options. Based on these results, we intend to rapidly advance our plans with the goal of allowing patients access as soon as possible.”
Ewing Sarcoma
As of the September 18, 2026, data cutoff, 60 patients (including 9 adolescent patients) were enrolled and treated with ozekibart plus IRI/TMZ, with 22 patients remaining on active treatment. Among the 51 response-evaluable patients, the combination demonstrated an overall response rate (ORR) of 62.7%, comprising 2 complete responses (CRs) and 30 partial responses (PRs). A total of 84.3% of response-evaluable patients (43/51) experienced measurable reduction in tumor size from baseline. An additional 12 patients achieved stable disease (SD), resulting in a Disease Control Rate (DCR) of 86.3%.
The median progression free survival (mPFS) was 6.0 months (95% CI: 4.6–7.4). Durable clinical benefit exceeding 6 months was observed in 18 patients (1 CR, 1 SD, 16 PRs), including 1 patient maintaining an ongoing PR for more than 2 years. At the cutoff date, 14 response-evaluable patients remained progression-free, including 2 patients with a PFS duration exceeding 12 months.
These data represent a meaningful improvement over historical benchmarks, such as irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma, which typically yield an ORR of approximately 15% to 30% and a mPFS of roughly 3 to 4 months.
The combination continued to demonstrate an acceptable and manageable safety profile consistent with the known cytotoxic toxicities of IRI/TMZ and DR5 agonism, with no evidence of unexpected cumulative hepatotoxicity.
The FDA accepted for filing our biologics license application for the potential approval of ozekibart in conventional chondrosarcoma. With approximately 300 new cases of Ewing sarcoma diagnosed each year in the U.S. and an estimated 2,500 individuals in the U.S. currently




living with Ewing sarcoma, the need for novel therapeutic options in this underserved community is profound, and we look forward to discussing these results with the FDA.
Presentation Materials
Ewing Sarcoma Poster Details:
•Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS)
•Session: Poster Presentation Session
•Abstract Number: 2465416
•Presenter: Varun Monga, M.D.
•Date: Thursday, November 19, 2026
The poster materials will be made available in the “Events & Presentations” section of the Inhibrx Biosciences investor portal at inhibrxbiosciences.investorroom.com.
About ozekibart (INBRX-109)
Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation. Ozekibart is engineered to optimize tumor-biased receptor clustering and activation without requiring secondary crosslinking, avoiding the severe hepatotoxicity observed with first-generation DR5-targeting agents.
About Inhibrx Biosciences, Inc.
Inhibrx is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx’s current clinical pipeline of therapeutic candidates includes ozekibart and ordastobart (INBRX-106), both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what Inhibrx believes to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.
Forward-Looking Statements
Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx’s judgments and beliefs regarding the strength of Inhibrx’s pipeline; statements regarding the safety and efficacy of its therapeutic candidate, ozekibart, based on topline and interim results; the potential for ozekibart to be used for the treatment of Ewing sarcoma and solid tumor indications; the clinical development of ozekibart, including data readouts, regulatory submissions and interactions, and the timing thereof; the potential commercial development of ozekibart; the potential approval by the FDA of ozekibart in unresectable or metastatic conventional chondrosarcoma; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials.




Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business, including, without limitation, risks and uncertainties regarding: topline data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline data; the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of topline, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and/or commercialization; the potential for its programs and prospects to be negatively impacted by developments relating to its competitors, including the results of studies or regulatory determinations relating to its competitors; the timing or likelihood of regulatory filings and approvals and regulatory developments in the U.S. and foreign countries; the successful commercialization of its therapeutic candidates, if approved; an accelerated development or approval pathway may not be available for ozekibart or other therapeutic candidates and any such pathway may not lead to a faster development process; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; and other risks described from time to time in the “Risk Factors” section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor and Media Contact:
Kelly Deck, CFO
ir@inhibrx.com
858-795-4260


Filing Exhibits & Attachments

4 documents

Keep reading